Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resusix vs FP24 in Acquired Coagulopathy
NCT03700723Phase 2Terminated
- Sponsor
- Entegrion
- Start
- Dec 2018
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Tissue Cells
- Countries
- 1
01
Overview
A Phase 2 trial of resusix in Acquired coagulopathy, sponsored by Entegrion. Started Dec 2018; status: terminated.
02
Drugs
resusix
03
Conditions
Acquired coagulopathy
Beyond the preview
Go deeper on NCT03700723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03700723.